ORIGINAL RESEARCH article

Front. Microbiol.

Sec. Infectious Agents and Disease

Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1592647

This article is part of the Research TopicResearch Advances and Challenges in Emerging and Re-Emerging Viral DiseasesView all 19 articles

Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques

Provisionally accepted
Jessica CoppolaJessica Coppola1Mara ParrenMara Parren1Raiza BastidasRaiza Bastidas1Karen SayeKaren Saye1Jacqueline MalvinJacqueline Malvin1Joseph G JardineJoseph G Jardine1Roxanne M GilbrideRoxanne M Gilbride2Sohita OjhaSohita Ojha2Shana FelthamShana Feltham2David MorrowDavid Morrow2Aaron Barber-AxthelmAaron Barber-Axthelm2Rachele BochartRachele Bochart2Randy FastRandy Fast3Kelli OswaldKelli Oswald3Rebecca ShoemakerRebecca Shoemaker3Jeffrey D LifsonJeffrey D Lifson3Louis J PickerLouis J Picker2*Dennis R BurtonDennis R Burton1*Scott G HansenScott G Hansen2*
  • 1Immunology & Microbial Science, The Scripps Research Institute, La Jolla, CA, United States
  • 2Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States
  • 3National Institutes of Health (NIH), Bethesda, Maryland, United States

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

A vaccine is widely regarded as necessary for the control of the HIV pandemic and eventual eradication of AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have both been shown capable of vaccine protection against the simian counterpart of HIV, SIV, in rhesus macaques. Here we provide preliminary evidence that combining these orthogonal antiviral mechanisms can provide increased protection against SIV challenge such that replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced in the presence of passively administered incompletely protective levels of neutralizing antibody. The report invites studies involving larger cohorts of macaques and alternate routes of providing neutralizing antibody.

Keywords: HIV, SIV, neutralizing antibodies, T cells, Vaccine, non-human primate (macaque)

Received: 14 Mar 2025; Accepted: 08 May 2025.

Copyright: © 2025 Coppola, Parren, Bastidas, Saye, Malvin, Jardine, Gilbride, Ojha, Feltham, Morrow, Barber-Axthelm, Bochart, Fast, Oswald, Shoemaker, Lifson, Picker, Burton and Hansen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Louis J Picker, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, 97006-3448, Oregon, United States
Dennis R Burton, Immunology & Microbial Science, The Scripps Research Institute, La Jolla, 92037, CA, United States
Scott G Hansen, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, 97006-3448, Oregon, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material